Agilent Technologies IncA
▲ PositiveCapitalrelevance
Agilent beat Q2 estimates and raised full-year EPS guidance.
Impact on stocks 1
Biotech & Genomic Medicine
Agilent Technologies IncAgilent Technologies reported better-than-expected second-quarter results, with revenue rising 8.1% year over year to $1.88 billion, beating analyst estimates of $1.84 billion, and adjusted earnings per share of $1.62, 9% above consensus. The company also guided third-quarter revenue to $1.99 billion at the midpoint, above expectations, and raised its full-year adjusted EPS guidance to $6.20 at the midpoint, a 2.4% increase. Management credited broad-based demand, strength in pharma, advanced materials, and diagnostics, as well as operational improvements from its Ignite Operating System and strategic pricing. China delivered 9% revenue growth, and the company highlighted momentum in biotech and semiconductor-related demand. Agilent's stock rose to $158.09 from $155.20 just before the earnings release.
Agilent Technologies IncAgilent beat Q2 estimates and raised full-year EPS guidance.